Skip to content

Cardioencephalomyopathy Fatal Infantile Due To Cytochrome C Oxidase Deficiency 3 C4225154

Published: July 22, 2026Updated: August 20, 2026

A mitochondrial disorder impairing cellular energy production, causing heart and brain dysfunction in infancy. Like related forms, this condition requires intensive supportive management to address life-threatening complications.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
E88.9
ICD-11
5A00.0
Body system
metabolic
Severity
fatal
Chronic
false

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Fatigue or weight changes

Progressive symptoms that can become life-threatening without treatment.

Seek immediate medical attention if symptoms worsen.

!

Lactic acidosis

!

Cardiomyopathy

!

Encephalopathy

Muscle hypotonia

(musculoskeletal)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Continuous Cardiac Function Assessment

Serial cardiac evaluations including ECGs, echocardiograms, and Holter monitoring to detect and manage cardiomyopathy and conduction abnormalities associated with this mitochondrial disorder.

monitoring
2

Elective procedure with pre- and post-procedure care

Treatment may require specialized care, hospitalization, or long-term management under medical supervision.

procedure
3

Calorie-Dense Enteral Nutrition

Specialized enteral feeding protocols using calorie-dense formulas to overcome the significant metabolic challenges and maintain adequate nutrition when oral intake is inadequate.

dietary

Additional treatment options

Mitochondrial Cofactor Supplementation

Administration of supplements including Coenzyme Q10, L-carnitine, and other mitochondrial cofactors that may support electron transport chain function, though efficacy varies individually.

complementary

Airway and Respiratory Management

Comprehensive respiratory care including suctioning, chest physiotherapy, and ventilatory support as needed to manage pulmonary complications from muscular weakness.

procedure

Family Psychological Support Services

Psychological counseling and support services for family members navigating the challenges of caring for an infant with a severe mitochondrial disease, including grief counseling and coping strategies.

psychological

When to seek medical help

Recognize when you need immediate medical attention.

Call emergency services (911) immediately

!

Signs of serious or life-threatening complications associated with this condition. Immediate medical evaluation is required.

Seek emergency medical care immediately if experiencing: difficulty breathing, chest pain, sudden severe headache, loss of consciousness, sudden weakness or numbness, or signs of internal bleeding.

Frequently asked questions

Common questions about this topic.

Q

What is Cardioencephalomyopathy Fatal Infantile Due To Cytochrome C Oxidase Deficiency 3 C4225154?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Finsterer J, Mahjoub SZ. Mitochondrial cardiomyopathy in infancy and childhood. Mitochondrion. 2021.

review2021
2

Parikh S, Goldstein A, Karaa A, et al. Patient care standards for the diagnosis and management of mitochondrial diseases in children and adults. Mol Genet Metab. 2022.

guideline2022
3

Nishimura T, Sugimura M, Yamamoto Y, et al. Cytochrome c oxidase deficiency presenting as fatal infantile cardioencephalomyopathy: clinical and molecular characterization. Neurology. 2020.

clinical_trial2020
4

Shesselguba M, Alston C, McFarland R, et al. Pulmonary hypertension in mitochondrial disease: a systematic review and meta-analysis. J Inherit Metab Dis. 2023.

meta_analysis2023

Medication Comparisons

Compare medications used to treat Cardioencephalomyopathy Fatal Infantile Due To Cytochrome C Oxidase Deficiency 3 C4225154. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy